Quick Read
- Novo Nordisk’s stock dropped nearly 10% after its Alzheimer’s trial failed to slow cognitive decline.
- Semaglutide improved biomarkers but did not impact disease progression in over 3,800 trial patients.
- Shares have lost over 50% in 2025, reflecting competition and strategic uncertainty.
- Novo Nordisk has cut drug prices and restructured leadership to combat market pressures.
- Analysts are divided on the company’s future, with continued focus on diabetes and obesity treatments.
Alzheimer’s Trial Miss: Novo Nordisk’s Gamble Doesn’t Pay Off
Novo Nordisk, once the pride of European pharmaceuticals, woke up to a stark reality in November 2025: its stock plunged nearly 10% in pre-market trading, closing at a four-year low. The reason? The company’s highly anticipated Alzheimer’s drug trial failed to meet its key target, shaking investor confidence and spotlighting the risks inherent in drug development.
The Phase 3 Evoke and Evoke+ trials enrolled over 3,800 adults with early-stage Alzheimer’s disease. Patients received oral semaglutide—better known as the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy—or a placebo, alongside standard care for two years. While semaglutide improved certain Alzheimer’s-related biomarkers, it did not slow the progression of cognitive decline as measured by the Clinical Dementia Rating score.
Novo’s chief scientific officer, Martin Holst Lange, described the trial as a “lottery ticket.” The company felt compelled to pursue the research, given the enormous unmet need for Alzheimer’s treatments, but acknowledged the odds of success were slim from the outset.
Stock Price Tumbles: A Year of Mounting Pressure
The failed Alzheimer’s trial was the latest in a string of setbacks for Novo Nordisk in 2025. Shares have tumbled more than 50% this year, erasing two-thirds of their value over the past 18 months. On November 21, the stock closed at $47.63, far below its 52-week high of $112.52. In Copenhagen, shares dropped to 274 Danish kroner ($42.33), marking the lowest point since 2021.
This decline isn’t just about the Alzheimer’s trial. Novo Nordisk has faced competitive pressure from rivals like Eli Lilly, whose Mounjaro and Zepbound drugs have surged ahead in the weight loss market. Lilly’s revenue growth has outpaced Novo’s, and its market cap recently hit $1 trillion. Meanwhile, Novo’s own sales growth has slowed, leading the company to cut its full-year guidance multiple times. Operating profit growth expectations fell to 4-7%, and sales growth to 8-11%.
Leadership Upheaval and Strategic Shifts
The market’s anxiety is not just about science—it’s about strategy. In response to falling sales and investor frustration, Novo Nordisk undertook a major restructuring. Former CEO Lars Fruergaard Jørgensen departed after eight years, replaced by Mike Doustdar, who slashed the global workforce by over 10% and refocused the company on its core diabetes and obesity businesses. The board saw a dramatic shake-up, with half its members replaced.
Novo also responded with aggressive pricing, cutting the cost of Ozempic and Wegovy for self-paying U.S. patients from $499 to $349 per month, and offering first-time patients their initial doses for just $199. The goal? To match Eli Lilly’s Zepbound and combat competition from telehealth providers like Hims & Hers Health, which offer compounded semaglutide at even lower prices using regulatory loopholes.
The company hopes the upcoming FDA decision on a tablet version of semaglutide for weight loss will help recapture market share from both traditional rivals and telehealth upstarts. Pills could appeal to patients wary of injections, a potential game-changer in the competitive obesity market.
Bidding Wars and Future Prospects
Novo Nordisk’s future hinges on more than Alzheimer’s. The company is locked in a $10 billion bidding war with Pfizer for Metsera, a biotech focused on obesity. Novo’s revised offer was deemed “superior” by Metsera, but Pfizer has challenged the bid as anticompetitive in court. CEO Doustdar insists Novo wouldn’t pursue the acquisition without confidence in closing the deal, emphasizing the need for complementary drugs to meet the demands of hundreds of millions of patients.
Despite the recent disappointment, semaglutide remains a cornerstone for Novo Nordisk. More than 37 million patient-years of exposure attest to its effectiveness for type 2 diabetes, obesity, and related conditions. Analysts note that, while the failed Alzheimer’s trial removes a near-term upside scenario, it doesn’t threaten the drug’s approved uses.
Analyst Sentiment: Divided Views, Cautious Outlook
The investment community is split. Jefferies downgraded Novo Nordisk to “underperform,” citing peak uncertainty. UBS remains neutral, forecasting continued struggles into 2026 and setting a price target of 340 kroner per share. Berenberg, on the other hand, sees potential for a rebound as the company adapts to its new reality.
Meanwhile, Eli Lilly and Biogen—other players in the Alzheimer’s space—saw relatively minor stock movements in response to Novo’s news. Eli Lilly’s shares dipped 1%, while Biogen’s rose 5%, reflecting differing expectations and market positions.
The Human Cost: Alzheimer’s and Unmet Needs
Alzheimer’s disease remains a devastating diagnosis, affecting over 55 million people worldwide. As populations age, the financial burden is expected to exceed $1 trillion by 2050. While smaller animal studies suggested that GLP-1 drugs like semaglutide could reduce neuroinflammation, this trial underscores the complexity of translating promising laboratory results into real-world treatments.
Novo Nordisk’s willingness to pursue Alzheimer’s research—despite a low likelihood of success—speaks to the company’s sense of responsibility, but also highlights the challenge of balancing innovation with investor expectations.
Looking Ahead: Can Novo Nordisk Regain Its Footing?
Novo Nordisk will present topline trial results at the Clinical Trials in Alzheimer’s Disease conference on December 3, with full data to follow at major scientific meetings in 2026. The company’s pipeline remains robust, and the fight for market share in obesity and diabetes continues.
For now, investors are left weighing the risks and rewards. Novo’s aggressive pricing, pursuit of new drug formats, and strategic acquisitions may help stabilize its position. But the failed Alzheimer’s trial serves as a cautionary tale—a reminder that scientific breakthroughs are never guaranteed, and that even market leaders must adapt to survive.
Based on the current facts, Novo Nordisk faces a crossroads: its core business remains strong, but its ambitions to expand into new therapeutic areas have met with reality checks. The company’s response—restructuring, price cuts, and renewed focus—shows resilience, yet the competitive and regulatory landscape means the road ahead will require both innovation and strategic clarity. The lesson for investors and industry alike is clear: in pharmaceuticals, leadership is earned not just by past success, but by the ability to navigate setbacks and seize new opportunities.